10-Q quarterly report · filed Nov 9, 2026

Oruka Therapeutics, Inc. (ORKA) Q3 2026 10-Q Quarterly Report

Short answer

Oruka Therapeutics, Inc. (ORKA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$50M
−65.0% YoY · −21.3% QoQ

Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) Q3 2026 10-Q on SEC EDGAR. USD.

Oruka Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved or sales revenue generated
  • Net loss $50.0M vs $30.3M YoY, operating margin not disclosed
  • R&D expenses $53.7M vs $29.0M, external costs $38.3M vs $15.6M
  • Cash, equivalents and securities $1.2B; operating cash use $101.0M for nine months
  • Financing $830.4M, including $658.3M offering proceeds and $161.4M ATM proceeds
  • Outlook: Phase 3 ORKA-001 trials planned first half 2027; losses expected to increase substantially

Risk Factors

  • Newly added manufacturing risk: BIOSECURE Act enacted December 2025, potentially restricting WuXi Biologics and forcing costlier supplier transitions
  • Most materially updated regulatory risk: FDA disruption following Trump administration layoffs and policy changes, potentially delaying reviews and clinical-trial authorizations
  • Clinical development risk: ORKA-001 Phase 3 expected first half of 2027, while Phase 2a and Phase 2b trials remain ongoing
  • Financial risk: April 2026 equity offering raised $658.3 million net, while August 2026 ATM capacity increased to $500.0 million, creating dilution risk
  • Operational risk: Sole-source supply for ORKA-001 and ORKA-002 leaves development vulnerable to supplier disruption

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Oruka Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.